Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study

by Alan Lenox-Smith, Catherine Reed, Jeremie Lebrec, Mark Belger, Roy W. Jones
Published 2016-11-01

Potential cost savings to be made by slowing cognitive decline in mild Alzheimer’s disease dementia using a model derived from the UK GERAS observational study

by Alan Lenox-Smith, Catherine Reed, Jeremie Lebrec, Mark Belger, Roy W. Jones
Published 2018-02-01

Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observati...

by Alonso Montoya, Jeremie Lebrec, Karen Mary Keane, Irene Fregenal, Antonio Ciudad, Ángel Moríñigo, Luis Agüera-Ortiz, Irene Romera, Inmaculada Gilaberte, Mark Zimmerman
Published 2016-10-01

Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes

by Roy W. Jones, Jeremie Lebrec, Kristin Kahle-Wrobleski, Grazia Dell’Agnello, Giuseppe Bruno, Bruno Vellas, Josep M. Argimon, Richard Dodel, Josep Maria Haro, Anders Wimo, Catherine Reed
Published 2017-03-01